YENOM NOTICIAS
Noticias financieras organizadas para conectar titulares, símbolos, fuente, fecha y sentimiento con tu análisis y operativa.
Si escribes ticker, YENOM prioriza ese instrumento. Si lo dejas vacío puedes explorar el feed general o por tema.
For the first time, Viola Davis shares her experience with shingles Viola encourages adults 50 years and older to prioritize their health and have candid conversations about increased risks that come with aging The partnership is part of G…
GSK (LSE:GSK) has entered a collaboration with Wave Life Sciences to advance a GalNAc-siRNA hepatology candidate into its development pipeline. The partnership with Wave Life Sciences focuses on RNA-based therapies targeting liver diseases…
GSK has pulled off a 52.5% share price gain over the past 5 years, yet with recent weakness on the screen, the live question for investors is whether that track record lines up with what the company is actually earning today. The issue is…
CROWN is the first large, phase IIIb international trial to evaluate the investigational use of long-acting Cabenuva versus daily oral therapy in people with a history of antiretroviral treatment and unsuppressed HIV Results build on LATIT…
The Trump administration has selected 10 companies, including AbbVie (ABBV [https://seekingalpha.com/symbol/ABBV]), Amgen (AMGN [https://seekingalpha.com/symbol/AMGN]), Pfizer (PFE [https://seekingalpha.com/symbol/PFE]), and GSK (GSK [http…
Markets are back to obsessing over central bank signals, supply routes and growth downgrades, and that mix is shaking up how investors look at reliable income. When credit feels tighter and headlines keep flagging disruption risks, steady…
[Cantor And John Thune Hold Press Conference On Economy] Alex Wong/Getty Images News * The Pharmaceutical Research and Manufacturers of America (PhRMA) has selected former Republican House Majority Leader Eric Cantor as its next CEO and pr…
Fresh funding from the Gates Foundation for AN2 Therapeutics' tuberculosis collaboration with GSK (LSE:GSK) has put the pharma group's boron based LeuRS inhibitor program back in focus for investors. The GSK share price has softened in the…
Hatteras Venture Partners – Hatteras holds first closing of Hatteras Opportunity Fund II (HOF II) – – HOF II closing brings capital under management to over $1 billion – DURHAM, N.C., Sept. 30, 2026 (GLOBE NEWSWIRE) -- Hatteras Venture Par…
[Measles] sefa ozel/iStock via Getty Images The CDC has updated its count of measles cases in the U.S. to indicate two deaths for this year, while Pennsylvania continues to report four measles-linked fatalities amid a dispute with the Heal…
GSK GSK and Sanofi SNY are two major European drugmakers with diversified portfolios spanning vaccines, specialty medicines and other pharmaceutical products. GSK has a strong presence in specialty medicines, vaccines and general medicines…
Merck MRK and partner Daiichi Sankyo announced that they have voluntarily withdrawn a regulatory filing with the FDA seeking accelerated approval for an investigational antibody-drug conjugate (ADC) called ifinatamab deruxtecan in lung can…
HUTCHMED (China) Limited First-in-class KRAS-payload leveraging synchronized EGFR inhibition HONG KONG and SHANGHAI and FLORHAM PARK, N.J., Sept. 27, 2026 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited ("HUTCHMED" or the "Company") (Nasdaq/A…
GSK plc (NYSE:GSK) has spent much of 2026 adding new drugs to its pipeline, and Berenberg is starting to think investors aren't giving it enough credit. Berenberg analyst Kerry Holford upgraded GSK from Hold to Buy and raised the firm's pr…
GSK plc (NYSE:GSK) is adding another cancer drug to a pipeline that has been getting considerably more attention under CEO Luke Miels. The company has agreed to acquire full global rights to a trispecific T-cell engager from China-based Ch…
On September 3, HUTCHMED (China) Limited (NASDAQ:HCM) announced an exclusive global development and licensing agreement with GSK plc (NYSE:GSK) for HMPL-A830, targeting colorectal, pancreatic, and lung cancers. Under the agreement, HUTCHME…
The Rockefeller Foundation becomes the first national philanthropy to commit to this regional initiative, triggering a matching commitment from the John M. Belk Endowment. $3.2 million in previously raised funds awarded to 11 community col…
[Medical syringe needle with measles, mumps, rubella label MR Or MMR vial of vaccine.] Md Ariful Islam/iStock via Getty Images * After weeks of resistance, the CDC has now acknowledged one of the four measles-related deaths [https://seekin…
Key Points Interested in GSK PLC Sponsored ADR? Here are five stocks we like better. GSK is targeting more than £40 billion in sales, above the £36.4 billion consensus estimate, with oncology assets—including antibody-drug conjugates, BLEN…
Britain's biggest pharmaceutical companies have warned the future of the industry is at risk as Europe loses ground to the US and China in medical research. AstraZeneca and GSK, along with European rivals Novo Nordisk, Sanofi, Roche and No…
During these busy times, it pays to stay on top of the latest profit opportunities. And today's blog post should be a great place to start. After taking a close look at the latest data on institutional buying pressure and each company's fu…
ALK Abello Tina A. Olesen, Executive Vice President for Corporate, Portfolio and Product StrategyTina A. Olesen has been appointed Executive Vice President for Corporate, Portfolio and Product Strategy at ALK, effective 1 October 2026. ALK…
Choosing between Axsome Therapeutics (NASDAQ:AXSM) and Moderna (NASDAQ:MRNA) requires balancing rapid commercial expansion against the potential of a massive, multi-use technology platform during a period of industrial shift. Axsome focuse…
M&A activity in the biotech sector has accelerated sharply in 2026, as large drugmakers increasingly turn to external innovation to strengthen pipelines, expand into new therapeutic areas and gain access to promising technologies and late-…
Nik Storonksy wants his digital bank to have a presence in Wall Street, not just London - Geoff Pugh Revolut is plotting a dual stock market listing in London and New York. The digital bank, valued at $115bn (£85bn), has previously shied a…
At the 2026 U.S. Conference on HIV/AIDS (USCHA), ViiV Healthcare and PAC recognize a decade of U=U and its landmark impact on the HIV community The organizations also announce, "Undetectable Voices," a new initiative elevating community vo…
GSK has delivered a solid multi year share price run, helped by fresh moves in oncology and vaccines, and that raises a simple question for investors who care about valuation. Is the current price you see on screen today adequately support…
Sir Keir Starmer's decision to invite Sir Pascal Soriot, AstraZeneca's chief executive, to Beijing at the beginning of the year was a textbook piece of modern diplomacy. The then-prime minister's attempt to revive economic cooperation rest…
GSK (LSE:GSK) agreed to acquire Chimagen's trispecific T cell-engager candidate for multiple myeloma, expanding its blood cancer research portfolio. The drug asset is described by the parties as a potential best in class trispecific T cell…
GSK plc GSK has entered into an agreement to acquire an investigational trispecific T-cell engager (TCE) from Chimagen Biosciences, a privately held biotechnology company. Under the agreement, GSK will pay Chimagen an upfront payment in ex…
GSK plc (NYSE:GSK) plans to close its vaccine manufacturing facility in Dresden, Germany, by summer 2027, putting 641 jobs at risk. The decision reflects declining demand for traditional egg-based flu vaccines, which has left GSK with more…
Ahead of the 2026 U.S. Conference on HIV/AIDS (USCHA), ViiV Healthcare announced it has funded 230 community-based organizations this year to strengthen essential HIV services and help connect people to HIV prevention and care DURHAM, N.C.…
GSK (GSK) agreed to acquire global rights to an experimental T-cell engager therapy for multiple mye PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium n…
[The Glaxosmithkline headquarters office building in Poznan. LOGO] Wirestock * GSK (GSK [https://seekingalpha.com/symbol/GSK]) has agreed to acquire full global rights to Chimagen Biosciences’ trispecific T-cell engager program for multipl…
Shares of Incyte INCY have rallied 23% year to date compared with the industry's growth of 5.2%. The stock has also outperformed the medical sector and the S&P 500 Index during this time frame. Much of this rally came after the company rep…
GSK plc GSK announced positive data from the registrational phase I/II ARROS-1 study evaluating its oncology drug, Jideytro (zidesamtinib), for the first-line treatment of patients with advanced or metastatic ROS1-positive non-small cell l…